Dow rises nearly 400 points as stocks rebound from last week’s selloff, amid vaccine hopes, deal-making

Dow surges 300 points as Apple leads tech rebound
September 14, 2020
DJ Oil Prices End With Sharp Gains on Supply Cuts — Market Talk
September 15, 2020

Dow rises nearly 400 points as stocks rebound from last week’s selloff, amid vaccine hopes, deal-making

Oracle said to beat Microsoft to forge strategic partnership with U.S. operations of TikTok

U.S. stocks rose Monday, taking back a chunk of last week’s losses amid fresh hope for a coronavirus vaccine and a flurry of potential corporate mash ups announced over the weekend, including reports that Oracle may be forging a partnership with TikTok, the popular China-owned social media platform.

How are equity benchmarks performing?

The Dow Jones Industrial Average DJIA, 1.32% rose 384 points, or 1.4%, to 28,049. The S&P 500 SPX, 1.50% added 54 points, or 1.6%, to 3,395. The Nasdaq Composite COMP, 1.87% climbed 216 points, or 2%, to 11,070.

Equities ended Friday with the Dow posting a weekly loss of 1.7%, while the S&P 500 fell 2.5% and the Nasdaq Composite Index dropped 4.1%, marking its worst weekly plunge since the period ended March 20, according to Dow Jones Market Data.

What’s driving the market?

Equities on Wall Street took on a buoyant tone at the start of the week as investors drew optimism from progress reported on the COVID-19 front, after market turbulence last week led the Nasdaq Composite to post its steepest weekly decline since the height of the pandemic-driven selloff in March.

“The market is moving up on several deals along with renewed hopes of a vaccine as AstraZeneca restarts trials and Pfizer’s CEO suggest a vaccine may be ready by year-end,” wrote Peter Cardillo, chief market economist at Spartan Capital Securities, in a Monday research note.

Notably, reports that the AstraZeneca PLC AZN, 0.82%  said over the weekend that clinical trials for its experimental coronavirus vaccine resumed after trials were paused due to an unexplained illness contracted by one of the participants who was given the vaccine. The restart of the trial for the vaccine may offer some optimism for the bulls to start the week.

In addition to the AstraZeneca report, Pfizer Inc.’s PFE, 3.72% CEO Albert Bourla in an interview with CBS News’ “Face the Nation,” on Sunday said that the pharmaceutical giant should know if its own experimental COVID-19 vaccine works by the end of October — and if approved, it could be distributed in the U.S. by the end of the year.

At the same time, some investors say they aren’t getting taken away by the prospects of a coronavirus vaccine, as it remains unclear how swiftly a successful vaccine candidate could be produced in mass quantities and handed out to the broader public.

“The arrival of a vaccine will be a game changer. But even if we start to see anything near broad distribution in the first quarter of next year, the turnaround is going to be gradual. As we have seen with testing, getting broad distribution and ubiquitous access isn’t trivial,” said James Meyer, chief investment officer at Tower Bridge Advisors.

A flourish of deal activity also was being digested as shares of Oracle CorpORCL, 5.06% jumped 4.9% after it was named a strategic partner for the U.S. operations of ByteDance-owned TikTok, according to The Wall Street Journal, citing people familiar with the matter. Such a deal would see Oracle beat Microsoft Corp., which also was seen as a front-runner in negotiations for a deal to own or operate the U.S. operations of TikTok.

Oracle confirmed that its name was submitted by ByteDance to serve as the “trusted technology provider” for TikTok, in a proposal given to the Treasury Department.

An agreement to link up TikTok with a U.S. company comes amid rising tensions between America and China, with President Donald Trump threatening repeatedly to shut down TikTok in the U.S. if it isn’t sold to an American company by Sept. 15.

Elsewhere on the tech scene, chip maker Nvidia Corp. NVDA, 5.31% was seen nearing a deal to buy British chip-designer Arm Holdings for more than $40 billion from SoftBank Group Corp. and drugmaker Gilead Sciences GILD, 3.03%  struck a deal to acquire Immunomedics IMMU, 98.65% and its breast-cancer drug Trodelvy for $21 billion, the Journal reported.

Which stocks are in focus?
  • Shares of Seattle Genetics SGEN, 15.19% rallied 10.2% on Monday after it announced two cancer-drug-related deals with Merck & Co. Inc.
  • Vaxart Inc.’s stock VXRT, 44.34% jumped 16.1% after the company said it had received the go-ahead from the Food and Drug Administration to begin testing its experimental oral COVID-19 vaccine in a Phase 1 clinical trial.
  • Verizon Communications Inc. VZ, 1.35%  announced Monday an agreement to buy mobile provider Tracfone from America Movil AMOV, +7.24% in a cash-and-stock deal that could be worth up to $6.9 billion. Verizon’s shares were marginally higher by 1.3%.
  • Wyndham Destinations IncWYND, 8.31% shares were up 4.7% after it said that gross vacation ownership, or VOI, sales came to $168 million in July and August with the trend improving in August from July.
  • Gilead Sciences Inc. GILD, 3.03% will pay $21 billion to buy biotech Immunomedics Inc. and its breast-cancer drug. Gilead’s shares gained 3.4%.
  • Tempur Sealy International Inc. TPX, 8.71% shares soared 8.6% after the mattress maker announced that it expects a 30% year-over-year increase in net sales in the third quarter
Which markets are on the move?

The 10-year Treasury note yield TMUBMUSD10Y, 0.663% was down 1 basis point to 0.66%. Bond prices move inversely to yields.

Gold futures GCZ20, 0.86% on the New York Mercantile Exchange were up 1.2% to $1,971 an ounce. Meanwhile, U.S. crude futures CL00, 0.16% were down 0.4% to $37.18 a barrel.

In global equities, the Stoxx Europe 600 index SXXP, +0.14% rose 0.2% and the U.K.’s FTSE 100 UKX, -0.09% ended with a 0.1% loss. Japan’s Nikkei NIK, +0.65%  closed 0.7% higher, while China’s CSI 300 index 000300, +0.51% gained 0.5%.

The ICE U.S. Dollar Index DXY, -0.28%, a measure of the greenback’s strength against its major rivals, weakened 0.4%.